Where I see patients (2)
Selected research
-
Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I-Metaiodobenzylguanidine Radiotherapy in the Anti-GD2 Immunotherapy Era.
Pediatric blood & cancer
-
Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I-Metaiodobenzylguanidine Radiotherapy in the Anti-GD2 Immunotherapy Era.
Pediatric blood & cancer
-
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study.
Pediatric blood & cancer
Clinical trials
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk N...
EFS time is calculated from date of randomization or assignment to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.
Recruiting
More about this study
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and D...
The number of patients experiencing a cycle 1 dose limiting toxicity at least possibly attributable to tegavivint by study part and dose level.
Recruiting
More about this study
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymp...
Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of CBL0137 in children with relapsed or refractory solid tumors including central nervous system (CNS) tumors and lymphoma.
Recruiting
More about this study
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine f...
Frequency percent (%) of patients with acute myeloid leukemia (AML) in second or greater relapse or refractory to relapse therapy who experience a cycle 1 dose limiting toxicity to imetelstat administered in combination with fluda...
Recruiting
More about this studyContact me
Tender wagging care
Our therapy dogs spread joy and smiles at the bedside and throughout the hospital.
Visit Child Life services